Overview

ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

Status:
Terminated
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
This study is intended to explore and evaluate the pharmacodynamics and clinical efficacy of the ionic contra-viral therapy CLS003 in immunocompromised and immunocompetent patients with benign and premalignant HPV-induced genital lesions
Phase:
Phase 2
Details
Lead Sponsor:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.
Treatments:
Digoxin
Furosemide